vs
GORMAN RUPP CO（GRC）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
GORMAN RUPP CO的季度营收约是再鼎医药的1.3倍（$166.6M vs $127.1M），再鼎医药同比增速更快（17.1% vs 2.4%），GORMAN RUPP CO自由现金流更多（$10.2M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 2.3%）
戈尔曼-拉普是一家总部位于俄亥俄州曼斯菲尔德的泵类制造商，产品面向市政供水、污水处理、工业、建筑、石油、消防及原始设备制造等多个领域提供配套水泵，公司在纽约证券交易所上市，现任首席执行官为斯科特·金。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
GRC vs ZLAB — 直观对比
营收规模更大
GRC
是对方的1.3倍
$127.1M
营收增速更快
ZLAB
高出14.7%
2.4%
自由现金流更多
GRC
多$36.9M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $166.6M | $127.1M |
| 净利润 | $13.7M | — |
| 毛利率 | 31.4% | 51.0% |
| 营业利润率 | 14.9% | -54.6% |
| 净利率 | 8.3% | — |
| 营收同比 | 2.4% | 17.1% |
| 净利润同比 | 25.2% | — |
| 每股收益（稀释后） | $0.53 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GRCZLAB
| Q4 25 | $166.6M | $127.1M | ||
| Q3 25 | $172.8M | $115.4M | ||
| Q2 25 | $179.0M | $109.1M | ||
| Q1 25 | $163.9M | $105.7M | ||
| Q4 24 | $162.7M | $108.5M | ||
| Q3 24 | $168.2M | $101.8M | ||
| Q2 24 | $169.5M | $100.1M | ||
| Q1 24 | $159.3M | $87.1M |
净利润GRCZLAB
| Q4 25 | $13.7M | — | ||
| Q3 25 | $11.3M | $-36.0M | ||
| Q2 25 | $15.8M | $-40.7M | ||
| Q1 25 | $12.1M | $-48.4M | ||
| Q4 24 | $11.0M | — | ||
| Q3 24 | $12.9M | $-41.7M | ||
| Q2 24 | $8.3M | $-80.3M | ||
| Q1 24 | $7.9M | $-53.5M |
毛利率GRCZLAB
| Q4 25 | 31.4% | 51.0% | ||
| Q3 25 | 29.2% | 59.5% | ||
| Q2 25 | 31.3% | 60.6% | ||
| Q1 25 | 30.7% | 63.6% | ||
| Q4 24 | 30.2% | 61.5% | ||
| Q3 24 | 31.3% | 64.1% | ||
| Q2 24 | 31.9% | 64.9% | ||
| Q1 24 | 30.4% | 61.4% |
营业利润率GRCZLAB
| Q4 25 | 14.9% | -54.6% | ||
| Q3 25 | 12.4% | -42.3% | ||
| Q2 25 | 15.0% | -50.3% | ||
| Q1 25 | 13.5% | -53.3% | ||
| Q4 24 | 13.0% | -62.6% | ||
| Q3 24 | 14.2% | -66.6% | ||
| Q2 24 | 15.4% | -76.0% | ||
| Q1 24 | 12.8% | -80.7% |
净利率GRCZLAB
| Q4 25 | 8.3% | — | ||
| Q3 25 | 6.6% | -31.2% | ||
| Q2 25 | 8.8% | -37.3% | ||
| Q1 25 | 7.4% | -45.8% | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 7.7% | -40.9% | ||
| Q2 24 | 4.9% | -80.2% | ||
| Q1 24 | 5.0% | -61.4% |
每股收益（稀释后）GRCZLAB
| Q4 25 | $0.53 | $-0.05 | ||
| Q3 25 | $0.43 | $-0.03 | ||
| Q2 25 | $0.60 | $-0.04 | ||
| Q1 25 | $0.46 | $-0.04 | ||
| Q4 24 | $0.42 | $-0.09 | ||
| Q3 24 | $0.49 | $-0.04 | ||
| Q2 24 | $0.32 | $-0.08 | ||
| Q1 24 | $0.30 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $35.1M | $689.6M |
| 总债务越低越好 | $307.5M | — |
| 股东权益账面价值 | $414.7M | $715.5M |
| 总资产 | $860.1M | $1.2B |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
现金及短期投资GRCZLAB
| Q4 25 | $35.1M | $689.6M | ||
| Q3 25 | $42.9M | $717.2M | ||
| Q2 25 | $27.0M | $732.2M | ||
| Q1 25 | $21.8M | $757.3M | ||
| Q4 24 | $24.2M | $779.7M | ||
| Q3 24 | $39.7M | $616.1M | ||
| Q2 24 | $34.2M | $630.0M | ||
| Q1 24 | $27.8M | $650.8M |
总债务GRCZLAB
| Q4 25 | $307.5M | — | ||
| Q3 25 | $322.3M | — | ||
| Q2 25 | $337.1M | — | ||
| Q1 25 | $352.2M | — | ||
| Q4 24 | $366.6M | — | ||
| Q3 24 | $381.0M | — | ||
| Q2 24 | $395.4M | — | ||
| Q1 24 | $400.7M | — |
股东权益GRCZLAB
| Q4 25 | $414.7M | $715.5M | ||
| Q3 25 | $405.2M | $759.9M | ||
| Q2 25 | $397.8M | $791.7M | ||
| Q1 25 | $382.1M | $810.8M | ||
| Q4 24 | $373.8M | $840.9M | ||
| Q3 24 | $367.3M | $667.7M | ||
| Q2 24 | $358.6M | $704.2M | ||
| Q1 24 | $353.7M | $762.2M |
总资产GRCZLAB
| Q4 25 | $860.1M | $1.2B | ||
| Q3 25 | $869.9M | $1.2B | ||
| Q2 25 | $861.8M | $1.2B | ||
| Q1 25 | $857.8M | $1.2B | ||
| Q4 24 | $858.5M | $1.2B | ||
| Q3 24 | $883.5M | $985.3M | ||
| Q2 24 | $891.1M | $987.4M | ||
| Q1 24 | $887.4M | $988.4M |
负债/权益比GRCZLAB
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.85× | — | ||
| Q1 25 | 0.92× | — | ||
| Q4 24 | 0.98× | — | ||
| Q3 24 | 1.04× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.0M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $10.2M | $-26.7M |
| 自由现金流率自由现金流/营收 | 6.1% | -21.0% |
| 资本支出强度资本支出/营收 | 2.9% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.09× | — |
| 过去12个月自由现金流最近4个季度 | $88.9M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流GRCZLAB
| Q4 25 | $15.0M | $-26.0M | ||
| Q3 25 | $42.3M | $-32.0M | ||
| Q2 25 | $27.8M | $-31.0M | ||
| Q1 25 | $21.1M | $-61.7M | ||
| Q4 24 | $9.3M | $-55.8M | ||
| Q3 24 | $27.2M | $-26.8M | ||
| Q2 24 | $22.7M | $-42.2M | ||
| Q1 24 | $10.7M | $-90.1M |
自由现金流GRCZLAB
| Q4 25 | $10.2M | $-26.7M | ||
| Q3 25 | $35.8M | $-35.0M | ||
| Q2 25 | $24.8M | $-33.9M | ||
| Q1 25 | $18.1M | $-63.2M | ||
| Q4 24 | $5.2M | $-58.4M | ||
| Q3 24 | $24.0M | $-28.2M | ||
| Q2 24 | $19.4M | $-42.9M | ||
| Q1 24 | $6.8M | $-91.1M |
自由现金流率GRCZLAB
| Q4 25 | 6.1% | -21.0% | ||
| Q3 25 | 20.7% | -30.4% | ||
| Q2 25 | 13.9% | -31.1% | ||
| Q1 25 | 11.0% | -59.9% | ||
| Q4 24 | 3.2% | -53.8% | ||
| Q3 24 | 14.3% | -27.7% | ||
| Q2 24 | 11.5% | -42.9% | ||
| Q1 24 | 4.3% | -104.5% |
资本支出强度GRCZLAB
| Q4 25 | 2.9% | 0.5% | ||
| Q3 25 | 3.8% | 2.6% | ||
| Q2 25 | 1.7% | 2.6% | ||
| Q1 25 | 1.8% | 1.5% | ||
| Q4 24 | 2.5% | 2.4% | ||
| Q3 24 | 1.9% | 1.3% | ||
| Q2 24 | 1.9% | 0.7% | ||
| Q1 24 | 2.5% | 1.1% |
现金转化率GRCZLAB
| Q4 25 | 1.09× | — | ||
| Q3 25 | 3.73× | — | ||
| Q2 25 | 1.76× | — | ||
| Q1 25 | 1.74× | — | ||
| Q4 24 | 0.84× | — | ||
| Q3 24 | 2.10× | — | ||
| Q2 24 | 2.72× | — | ||
| Q1 24 | 1.36× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GRC
| Industrial | $34.7M | 21% |
| Fire Market | $31.4M | 19% |
| Municipal | $25.3M | 15% |
| Agriculture | $22.5M | 14% |
| Repair Parts | $18.9M | 11% |
| Construction | $17.3M | 10% |
| Original Equipment Manufacturer | $10.8M | 7% |
| Petroleum | $5.6M | 3% |
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
